Brief: US FDA Accepts Priority Review For Deciphera's New Drug Application For Vimseltinib
15/08/2024 23:07
Aug 15 (Reuters) - Ono Pharmaceutical Co Ltd 4528.T :
* U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS FOR PRIORITY
REVIEW
DECIPHERA’S NEW DRUG APPLICATION FOR VIMSELTINIB FOR THE
TREATMENT OF PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT)
* ONO PHARMACEUTICAL CO LTD - U.S. FDA HAS ASSIGNED A TARGET
ACTION DATE OF FEBRUARY 17, 2025
Source text for Eikon: ID:nBw6Y7JQna
Further company coverage: 4528.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ONO PHARMACEUTICAL
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours